Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability PARIS–(BUSINESS WIRE)–Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of … [Read more…]
Results from a global survey of over 4,300 women across five continents presented at IMCAS 2026 reveal a knowledge gap on the impact of menopause on the skin, despite women experiencing around three skin changes during menopause1 Galderma will also host a symposium delving into the challenges and science behind menopause-related skin changes and aesthetic … [Read more…]
LAS VEGAS–(BUSINESS WIRE)–From the only company selling nutraceutical products containing the neuroprotective dietary ingredient G-Agmatine®, Gilad&Gilad is excited to announce the launch of AgmaVet® For Horses, a new product dedicated to promoting resilient nerve functions and alleviate joints discomfort. Osteoarticular (OA), or joints, health deterioration is very common in animals, as it is in humans. … [Read more…]
Record Q2 Revenues of $464 Million (11% year-over-year growth) Q2 Earnings per Diluted Share GAAP EPS of $2.22 Record Non-GAAP EPS of $2.58 Q2 Operating Cash Flow of $62 Million Company Increases Fiscal 2026 Non-GAAP EPS Guidance HAWTHORNE, Calif.–(BUSINESS WIRE)–OSI Systems, Inc. (the “Company” or “OSI Systems”) (NASDAQ: OSIS) today announced its financial results for … [Read more…]
Higher Adult Vaccination Could Have Prevented Tens of Thousands of Deaths UPPER NYACK, N.Y.–(BUSINESS WIRE)–A Global Healthy Living Foundation (GHLF) study showed seasonal influenza continues to impose a massive and largely preventable economic and human toll on the United States. According to the newly released paper, “Influenza’s Economic Burden and the Impact of Adult Vaccination,” … [Read more…]
Stephenson Global Scholar Grants accelerate breakthrough research aimed at ending pancreatic cancer — Applications open now through February 25. LOS ANGELES–(BUSINESS WIRE)–The Stephenson Global Pancreatic Cancer Research Institute (SGPCRI) today announced the opening of applications for its 2026 Stephenson Global Scholar Grants, a global funding opportunity in partnership with City of Hope, one of the … [Read more…]
LEXINGTON, Ky.–(BUSINESS WIRE)–#Biomanufacturing—Demeetra AgBio, a genome engineering company enabling research and biomanufacturing through advanced gene-editing technologies and engineered CHO host cells, announced the completion and full integration of its acquisition of Hera BioLabs. The transaction, completed June 1, resulted in Demeetra now holding expanded rights to the hyperactive Super piggyBac® transposase platform and technologies, establishing … [Read more…]
China’s National Medical Products Administration (NMPA) has approved Seysara® (sarecycline hydrochloride) for the treatment of inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in patients 9 years of age and older. Sarecycline hydrochloride is an innovative tetracycline-derived oral antibiotic treatment – the first that was specifically developed for use in dermatology. Almirall has entered into a … [Read more…]
U.S. FDA Approves YUVEZZI™ as the only dual-agent, once daily presbyopia-correcting eye drop LONDON & SEATTLE–(BUSINESS WIRE)–Tenpoint Therapeutics, Ltd., a global, commercial biotechnology company focused on developing groundbreaking treatments to rejuvenate vision in the aging eye, today announced it has secured $235 million through the successful close of its Series B preferred stock financing and … [Read more…]
YUVEZZI (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1% is the only dual-agent presbyopia-correcting eye drop intentionally designed to deliver durability, tolerability, and safety YUVEZZI was studied in two pivotal Phase 3 trials enrolling more than 800 patients, including the world’s largest and longest safety study for presbyopia eye drops1,2 YUVEZZI achieves miosis from 30-minutes up … [Read more…]
